Intellia Therapeutics, Inc. (NTLA) Insider Trading Disclosures
Intellia Therapeutics, Inc. (NTLA) is a publicly traded company on the Nasdaq, categorized under SIC 2835 (In Vitro & In Vivo Diagnostic Substances). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: NTLA
CIK: 1652130
Exchange: Nasdaq
SIC 2835: In Vitro & In Vivo Diagnostic Substances
Fiscal Year End: 12/31
State: DE
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
Deloitte & Touche LLP
Auditor SinceSince 12/31/2016 12:00:00 AM
Lead Engagement PartnerJames Holmes
Audit LocationBoston, Massachusetts, United States
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| 4 | 2026-10-06 | 2026-10-02 | 4 | 0001193125-26-415541 | View SEC Doc Filr Page |
| 144 | 2026-10-05 | — | 144 Filing | 0001950047-26-010054 | View SEC Doc Filr Page |
| 8-K | 2026-09-08 | 2026-09-08 | 8-K | 0001193125-26-385194 | View SEC Doc Filr Page |
| 8-K | 2026-09-04 | 2026-09-04 | 8-K | 0001193125-26-383645 | View SEC Doc Filr Page |
| 4 | 2026-08-24 | 2026-08-20 | 4 | 0001193125-26-363567 | View SEC Doc Filr Page |
| 144 | 2026-08-20 | — | 144 Filing | 0001969223-26-000938 | View SEC Doc Filr Page |
| SCHEDULE 13G | 2026-08-07 | — | SCHEDULE 13G Filing | 0000093751-26-000484 | View SEC Doc Filr Page |
| 10-Q | 2026-08-06 | 2026-06-30 | 10-Q | 0001193125-26-337952 | View SEC Doc Filr Page |
| 8-K | 2026-08-06 | 2026-08-06 | 8-K | 0001193125-26-336772 | View SEC Doc Filr Page |
| 4 | 2026-07-24 | 2026-07-22 | 4 | 0001193125-26-316279 | View SEC Doc Filr Page |
| 4 | 2026-07-06 | 2026-07-01 | 4 | 0002019493-26-000002 | View SEC Doc Filr Page |
| 4 | 2026-07-06 | 2026-07-02 | 4 | 0001821530-26-000002 | View SEC Doc Filr Page |
| 144 | 2026-07-02 | — | 144 Filing | 0001950047-26-006836 | View SEC Doc Filr Page |
| 8-K | 2026-06-15 | 2026-06-13 | 8-K | 0001193125-26-270358 | View SEC Doc Filr Page |
| 4 | 2026-06-10 | 2026-06-09 | 4 | 0001545794-26-000001 | View SEC Doc Filr Page |
| 4 | 2026-06-10 | 2026-06-09 | 4 | 0001193125-26-266241 | View SEC Doc Filr Page |
| 4 | 2026-06-10 | 2026-06-09 | 4 | 0001756929-26-000002 | View SEC Doc Filr Page |
| 4 | 2026-06-10 | 2026-06-09 | 4 | 0001193125-26-266236 | View SEC Doc Filr Page |
| 4 | 2026-06-10 | 2026-06-09 | 4 | 0001193125-26-266233 | View SEC Doc Filr Page |
| 4 | 2026-06-10 | 2026-06-09 | 4 | 0001563572-26-000001 | View SEC Doc Filr Page |
| 4 | 2026-06-10 | 2026-06-09 | 4 | 0001193125-26-266230 | View SEC Doc Filr Page |
| 8-K | 2026-06-10 | 2026-06-09 | 8-K | 0001193125-26-265934 | View SEC Doc Filr Page |
| 10-Q | 2026-05-11 | 2026-03-31 | 10-Q | 0001193125-26-215740 | View SEC Doc Filr Page |
| 8-K | 2026-05-11 | 2026-05-11 | 8-K | 0001193125-26-215721 | View SEC Doc Filr Page |
| 8-K | 2026-04-30 | 2026-04-27 | 8-K | 0001193125-26-197489 | View SEC Doc Filr Page |